When you go to “COOKIES INCL. ALLOW US SERVICES” click, you agree to the storage of cookies on your device to improve website navigation, analyze site usage, and support our marketing efforts. For more information, see our Privacy statement.

27.6.2023

Haemo Pharma and Winback announce Cooperation

Haemo Pharma and WINBACK announce exclusive sales cooperation for Winback Tecar therapy devices in Austria.

A therapist treats a patient's arm with a Winback device, as part of the newly announced sales cooperation between Haemo Pharma and Winback.

Haemo Pharma and Winback, a renowned French manufacturer of medical therapy equipment, have an exclusive sales cooperation for Winback TECAR therapy devices completed for the Austrian market.

The collaboration between Haemo Pharma and Winback aims to strengthen the presence and access to the cutting-edge Winback TECAR therapy equipment in medical facilities, clinics and physiotherapy centers across Austria.
The innovative therapy devices use capacitive and resistive electrotherapy technologies to provide targeted treatments for lesions, pain, and muscular injuries, including rehabilitation, pain relief, and regeneration.

Mag. Markus Mateyka, managing director of Haemo Pharma, emphasized the importance of this cooperation: “Winback TECAR therapy devices are leaders in their category and offer advanced technology to improve patient care. We are proud to add these innovative devices to our portfolio and to provide our customers in the Austrian healthcare sector with access to this innovative therapy.”

This exclusive sales cooperation between Haemo Pharma and Winback is a significant step towards establishing Winback TECAR therapy devices in the Austrian medical landscape. Healthcare professionals and institutions can now rely on cutting-edge technologies to accelerate their patients' recovery and optimize their outcomes.

To the Winback product page

Für weitere Informationen kontaktieren Sie bitte:

More posts

Product Update

Long-term study proves lasting success with HyaloFast

A recent long-term study (Whyte et al. 2024) confirms the sustainable effectiveness of HyaloFast.
Sponsoring

Haemo Pharma as ADMIRA Wacker's new healthcare partner

Hämo Pharma is pleased to announce its partnership with the traditional soccer club ADMIRA Wacker.
Product Presentation

Stem cell therapy for degenerative joint diseases

In an Ö24 interview, Prof. Dr. Zimpfer provides insights into stem cell therapy and new approaches .

Make evidence-based decisions

Learn more about our scientifically researched products. Please feel free to contact us for further information.